“Bill brings to Cohera extensive industry knowledge and experience guiding product manufacturing from early-stage R&D through worldwide commercialization,” said Patrick Daly, president and chief executive officer of Cohera Medical. “His experience will be invaluable to our company as we ramp up manufacturing activities in preparation for TissuGlu clinical trials.”
Cotter spent 10 years of tenure as the vice president of operations for Closure Medical Corporation a medical device company, acquired by Johnson & Johnson, which developed the world’s first synthetic topical skin adhesive to be approved by the US Food and Drug Administration. Before to join Closure Medical Corporation, he was vice president of operations with Sanofi Diagnostics Pasteur, where he had direct responsibility for all North American manufacturing sites and chaired the worldwide manufacturing committee. Bill is listed as co-inventor on eight US patents and has a bachelor’s degree from Ohio University.
